Literature DB >> 11779513

Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction.

Dirk H Walter1, Stephan Fichtlscherer, Martina B Britten, Wolfgang Auch-Schwelk, Volker Schächinger, Andreas M Zeiher.   

Abstract

Statin therapy reduces clinical events in patients with stable coronary artery disease. Recent data indicate that the beneficial effects of statin therapy may also extend to patients experiencing an acute ischemic coronary event. However, the potential role of statins to further modify clinical outcome in patients undergoing coronary stent implantation has not been addressed. Therefore, we investigated whether the initiation of statin therapy immediately after successful coronary stent implantation improves short-term clinical outcome in 704 patients (335 patients with stable angina pectoris [AP], 224 patients with unstable AP, and 145 patients with Q-wave acute myocardial infarction [AMI]). Compared with the lowest risk group (patients with stable AP receiving statin therapy), patients with unstable AP (RR 6.9, 95% confidence interval [CI] 1.5 to 31, p = 0.004) and patients with Q-wave AMI (RR 7.6, 95% CI 1.5 to 37, p = 0.004) experienced an increased risk for the occurrence of the primary combined end point of cardiac death and AMI. Importantly, initiation of statin therapy abrogated the increased risk in patients with unstable AP to the level of patients with stable AP receiving statin therapy (RR 1.5, 95% CI 0.2 to 11, p = 0.7). In contrast, statin therapy did not affect the RR in patients with Q-wave AMI during 6-month follow-up (RR 7.9, 95% CI 1.6 to 39 vs RR 7.6, 95% CI 1.5 to 37, p = NS). The beneficial effects of statin therapy after successful coronary stent implantation in unstable AP were most prominent during the first 4 weeks after the ischemic episode. Statins appear to contribute to the rapid transformation of unstable coronary artery disease into a stable condition with a very low event rate over the forthcoming 6 months in patients with unstable AP undergoing successful coronary stent implantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779513     DOI: 10.1016/s0002-9149(01)02153-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.

Authors:  Jessica M Ma; Cynthia A Jackevicius; Uchenwa Genus; Vladimir Dzavik
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

Review 2.  Early use of statins in acute coronary syndromes.

Authors:  Joshua M Spin; Randall H Vagelos
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 3.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

Review 5.  Early use of statins in acute coronary syndromes.

Authors:  Joshua M Spin; Randall H Vagelos
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

6.  Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).

Authors:  C H Lee; P de Feyter; P W Serruys; F Saia; P A Lemos; D Goedhart; P R Soares; V A W M Umans; M Ciccone; M Cortellaro
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 7.  Ongoing clinical trials of the pleiotropic effects of statins.

Authors:  Jean Davignon; Lawrence A Leiter
Journal:  Vasc Health Risk Manag       Date:  2005

8.  Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].

Authors:  Petr Ostadal; David Alan; Petr Hajek; Jiri Vejvoda; Martin Mates; Peter Blasko; Josef Veselka; Milan Kvapil; Jiri Kettner; Martin Wiendl; Ondrej Aschermann; Josef Slaby; Eduard Nemecek; Frantisek Holm; Marek Rac; Milan Macek; Jana Cepova
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-03-24

9.  Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction.

Authors:  Taehoon Ahn; Soon Yong Suh; Kyounghoon Lee; Woong Chol Kang; Seung Hwan Han; Youngkeun Ahn; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2016-11-24       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.